Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.

<h4>Background</h4>The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN). We investigated the efficacy and outcome of this protocol as a f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ramon Andrade de Mello, Sandra Gerós, Marcos Pantarotto Alves, Filipa Moreira, Isabel Avezedo, José Dinis
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1853c6527bd840abb60a2677418f82d5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1853c6527bd840abb60a2677418f82d5
record_format	dspace
spelling	oai:doaj.org-article:1853c6527bd840abb60a2677418f82d52021-11-18T08:33:30ZCetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.1932-620310.1371/journal.pone.0086697https://doaj.org/article/1853c6527bd840abb60a2677418f82d52014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24516537/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN). We investigated the efficacy and outcome of this protocol as a first-line treatment for patients with recurrent or metastatic disease. We evaluated overall-survival (OS), progression-free-survival (PFS), overall response rate (ORR) and the treatment toxicity profile in a retrospective cohort.<h4>Patients and methods</h4>This study enrolled 121 patients with untreated recurrent or metastatic SCCHN. The patients received PF+ cetuximab every 3 weeks for a maximum of 6 cycles. Patients with stable disease who received PF+ cetuximab continued to receive cetuximab until disease progressed or unacceptable toxic effects were experienced, whichever occurred first.<h4>Results</h4>The median patient age was 53 (37-78) years. The patient cohort was 86.8% male. The addition of cetuximab to PF in the recurrent or metastatic setting provided an OS of 11 months (Confidential Interval, CI, 95%, 8.684-13.316) and PFS of 8 months (CI 95%, 6.051-9.949). The disease control rate was 48.9%, and the ORR was 23.91%. The most common grade 3 or 4 adverse events in the PF+ cetuximab regimen were febrile neutropenia (5.7%), skin rash (3.8%) and mucosistis (3.8%).<h4>Conclusions</h4>The results of this study suggest that cetuximab plus platinum-fluorouracil chemotherapy is a good option for systemic treatment in advanced SSCHN patients. This regimen has a well-tolerated toxicity profile.Ramon Andrade de MelloSandra GerósMarcos Pantarotto AlvesFilipa MoreiraIsabel AvezedoJosé DinisPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 2, p e86697 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ramon Andrade de Mello Sandra Gerós Marcos Pantarotto Alves Filipa Moreira Isabel Avezedo José Dinis Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
description	<h4>Background</h4>The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN). We investigated the efficacy and outcome of this protocol as a first-line treatment for patients with recurrent or metastatic disease. We evaluated overall-survival (OS), progression-free-survival (PFS), overall response rate (ORR) and the treatment toxicity profile in a retrospective cohort.<h4>Patients and methods</h4>This study enrolled 121 patients with untreated recurrent or metastatic SCCHN. The patients received PF+ cetuximab every 3 weeks for a maximum of 6 cycles. Patients with stable disease who received PF+ cetuximab continued to receive cetuximab until disease progressed or unacceptable toxic effects were experienced, whichever occurred first.<h4>Results</h4>The median patient age was 53 (37-78) years. The patient cohort was 86.8% male. The addition of cetuximab to PF in the recurrent or metastatic setting provided an OS of 11 months (Confidential Interval, CI, 95%, 8.684-13.316) and PFS of 8 months (CI 95%, 6.051-9.949). The disease control rate was 48.9%, and the ORR was 23.91%. The most common grade 3 or 4 adverse events in the PF+ cetuximab regimen were febrile neutropenia (5.7%), skin rash (3.8%) and mucosistis (3.8%).<h4>Conclusions</h4>The results of this study suggest that cetuximab plus platinum-fluorouracil chemotherapy is a good option for systemic treatment in advanced SSCHN patients. This regimen has a well-tolerated toxicity profile.
format	article
author	Ramon Andrade de Mello Sandra Gerós Marcos Pantarotto Alves Filipa Moreira Isabel Avezedo José Dinis
author_facet	Ramon Andrade de Mello Sandra Gerós Marcos Pantarotto Alves Filipa Moreira Isabel Avezedo José Dinis
author_sort	Ramon Andrade de Mello
title	Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
title_short	Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
title_full	Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
title_fullStr	Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
title_full_unstemmed	Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
title_sort	cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive european cancer institution.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/1853c6527bd840abb60a2677418f82d5
work_keys_str_mv	AT ramonandradedemello cetuximabplusplatinumbasedchemotherapyinheadandnecksquamouscellcarcinomaaretrospectivestudyinasinglecomprehensiveeuropeancancerinstitution AT sandrageros cetuximabplusplatinumbasedchemotherapyinheadandnecksquamouscellcarcinomaaretrospectivestudyinasinglecomprehensiveeuropeancancerinstitution AT marcospantarottoalves cetuximabplusplatinumbasedchemotherapyinheadandnecksquamouscellcarcinomaaretrospectivestudyinasinglecomprehensiveeuropeancancerinstitution AT filipamoreira cetuximabplusplatinumbasedchemotherapyinheadandnecksquamouscellcarcinomaaretrospectivestudyinasinglecomprehensiveeuropeancancerinstitution AT isabelavezedo cetuximabplusplatinumbasedchemotherapyinheadandnecksquamouscellcarcinomaaretrospectivestudyinasinglecomprehensiveeuropeancancerinstitution AT josedinis cetuximabplusplatinumbasedchemotherapyinheadandnecksquamouscellcarcinomaaretrospectivestudyinasinglecomprehensiveeuropeancancerinstitution
_version_	1718421605666783232

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.

Ejemplares similares